AbCellera Biologics (ABCL) Earnings Date, Estimates & Call Transcripts $2.65 -0.11 (-3.99%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AbCellera Biologics Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 18EstimatedActual EPS (Nov. 4) -$0.17 Missed By -$0.03 Consensus EPS (Nov. 4) -$0.14 AbCellera Biologics announced Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.17, which missed the consensus estimate of -$0.14 by $0.03. Quarterly revenue was reported to be $6.51 million, below the consensus estimate of $8.95 million. With a trailing EPS of -$0.61, AbCellera Biologics' earnings are expected to decrease next year, from ($0.59) to ($0.72) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckABCL Upcoming EarningsAbCellera Biologics' next earnings date is estimated for Tuesday, February 18, 2025, based off prior year's reporting schedules. Get AbCellera Biologics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbCellera Biologics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataABCL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ABCL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin AnalyticsTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. AbCellera Biologics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243-$0.14-$0.08-$0.11Q2 20243-$0.15-$0.09-$0.13Q3 20243-$0.14-$0.05-$0.09Q4 20243-$0.15-$0.09-$0.11FY 202412-$0.58-$0.31-$0.45Q1 20251-$0.15-$0.15-$0.15Q2 20251-$0.15-$0.15-$0.15Q3 20251-$0.16-$0.16-$0.16Q4 20251-$0.17-$0.17-$0.17FY 20254($0.63)($0.63)($0.63) AbCellera Biologics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/18/2025(Estimated)------- 11/4/2024Q3 2024-$0.14-$0.17 -$0.03-$0.17$8.95M$6.51M 8/6/2024Q2 2024-$0.15-$0.13+$0.02-$0.13$10.12M$7.30M 5/7/2024Q1 2024-$0.16-$0.14+$0.02-$0.14$10.73M$9.95M 2/20/2024Q4 2023-$0.14-$0.17 -$0.03-$0.17$9.58M$9.18M 11/2/2023Q3 2023-$0.14-$0.10+$0.04-$0.10$11.92M$6.60M 8/3/2023Q2 2023-$0.13-$0.11+$0.02-$0.11$12.38M$10.10M Missed Nvidia? Watch this ASAP (Ad)This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know.5/4/2023Q1 2023-$0.12-$0.14 -$0.02-$0.14$12.11M$12.20M 2/21/2023Q4 2022$0.01-$0.10 -$0.11-$0.10$50.80M$21.50M AbCellera Biologics Earnings - Frequently Asked Questions When is AbCellera Biologics's earnings date? AbCellera Biologics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates. Learn more on ABCL's earnings history. Did AbCellera Biologics beat their earnings estimates last quarter? In the previous quarter, AbCellera Biologics (NASDAQ:ABCL) missed the analysts' consensus estimate of ($0.14) by $0.03 with a reported earnings per share (EPS) of ($0.17). Learn more on analysts' earnings estimate vs. ABCL's actual earnings. How can I listen to AbCellera Biologics's earnings conference call? The conference call for AbCellera Biologics's latest earnings report can be listened to online. Listen to Conference Call How can I read AbCellera Biologics's conference call transcript? The conference call transcript for AbCellera Biologics's latest earnings report can be read online. Read Transcript How much revenue does AbCellera Biologics generate each year? AbCellera Biologics (NASDAQ:ABCL) has a recorded annual revenue of $38.03 million. How much profit does AbCellera Biologics generate each year? AbCellera Biologics (NASDAQ:ABCL) has a recorded net income of -$146.40 million. ABCL has generated -$0.61 earnings per share over the last four quarters. What is AbCellera Biologics's EPS forecast for next year? AbCellera Biologics's earnings are expected to decrease from ($0.59) per share to ($0.72) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Bausch Health Companies Earnings Results MoonLake Immunotherapeutics Earnings Results Agios Pharmaceuticals Earnings Results Xenon Pharmaceuticals Earnings Results PTC Therapeutics Earnings Results Edgewise Therapeutics Earnings Results Amicus Therapeutics Earnings Results Dyne Therapeutics Earnings Results MorphoSys Earnings Results Verona Pharma Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run Tech funds are hemorrhaging cash: Sell this stock now (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. This page (NASDAQ:ABCL) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding AbCellera Biologics Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.